XIAP and melanoma: The results suggest that melphalan-exposed human melanoma cells trigger an activation of the immune system, as shown by expansion of CD16+ monocytic cells and activation of cytotoxic T cells and that these events may contribute to the clinical efficacy of M-ILP.